Jun 12, 2020
AbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks
Apr 01, 2020
Salimetrics' Growing List of Cytokines Which Can Be Reliably Tested in Saliva Now Includes IL-17A, IL-5, and IL-7 for Fast, Easy Salivary Biomarker Analysis
Jan 14, 2020
New Head-to-Head Phase 3 Data Show SKYRIZI(TM) (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks
Oct 02, 2019
Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
Sep 13, 2019
Novartis' Cosentyx and Pfizer's Xeljanz Leave the Most on the Table with Psoriatic Arthritis Switch Brands, According to Spherix Global Insights
Sep 11, 2019
Interleukin Inhibitors Market Worth $74.6 Billion by 2026 | CAGR: 17.4%: Grand View Research, Inc.
Jun 04, 2019
Psoriatic Arthritis Market and Forecast Analysis 2035
Jan 28, 2019
Novartis data show psoriasis patients treated with Cosentyx® reported improvements in quality of life measures as early as Week 4
Dec 12, 2018
New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48
Oct 22, 2018
Novartis presents new Cosentyx® data demonstrating long-term response and safety in ankylosing spondylitis
Jun 19, 2018
Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis
Feb 16, 2018
Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
Feb 16, 2018
New TREMFYA® (guselkumab) Data Demonstrates Long-Term Skin Clearance In Patients With Moderate To Severe Plaque Psoriasis
Feb 08, 2018
Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis
Jan 16, 2018
Novartis new data reinforces superiority of Cosentyx® versus Stelara® in achieving skin clearance for psoriasis patients
Dec 07, 2017
Novartis initiates study evaluating impact of higher dosing of Cosentyx® in patients with ankylosing spondylitis
Dec 04, 2017
Eli Lilly's Taltz Now Approved for Psoriatic Arthritis, Bringing Key Competition for Rival IL-17 Inhibitor, Novartis' Cosentyx
Nov 29, 2017
Dermatologists' Six Month Projections Reveal Janssen's Tremfya Closing in on the IL-17 Inhibitors, Novartis' Cosentyx and Eli Lilly's Taltz, in Psoriasis
Nov 15, 2017
Janssen Inc. Announces Health Canada Approval of TREMFYA(TM) (guselkumab) for the Treatment of Adult Moderate to Severe Plaque Psoriasis
Nov 07, 2017
Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage